Adial Pharmaceuticals, Inc. (ADIL) Research

Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.

Market snapshot

Symbol
ADIL
Price
$2.60
Day change
-5.45%
Market cap
$2.5M
P/E ratio
-0.46x
52-week range
1.31-19
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$7.00

Peer companies

  • Acurx Pharmaceuticals, Inc. (ACXP)
  • Aprea Therapeutics, Inc. (APRE)
  • BioCardia, Inc. (BCDA)
  • Brainstorm Cell Therapeutics Inc. (BCLI)
  • Cardio Diagnostics Holdings, Inc. (CDIO)
  • Creative Medical Technology Holdings, Inc. (CELZ)
  • HCW Biologics Inc. (HCWB)
  • Kiora Pharmaceuticals, Inc. (KPRX)

Recent insider activity

  • Davidson Matt — A-Award (232417 shares) on 2026-06-12
  • Davidson Matt — A-Award (232417 shares) on 2026-06-12
  • Davidson Matt — A-Award (61647 shares) on 2026-06-11
  • Davidson Matt — A-Award (3427 shares) on 2026-06-11
  • Davidson Matt — A-Award (101.298 shares) on 2026-06-11

Open Adial Pharmaceuticals, Inc. (ADIL) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.